Reaction
Cytogenetic Abnormality reporting signals
As of the last recalculation, Cytogenetic Abnormality appears in 1,120 FAERS reports alongside 32 co-occurring drug terms. The strongest observed disproportionality signal is IMATINIB (PRR 50.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Imatinib | 46 | 50.5 | 50.6 |
| Tretinoin | 17 | 39.5 | 39.6 |
| Zonisamide | 28 | 36.1 | 36.1 |
| Atazanavir | 23 | 30.3 | 30.4 |
| Mercaptopurine | 24 | 26.3 | 26.3 |
| Etoposide | 83 | 22.6 | 22.6 |
| Lacosamide | 43 | 22.3 | 22.3 |
| Ritonavir 100 Mg | 16 | 20.2 | 20.2 |
| Ritonavir | 30 | 19.6 | 19.6 |
| Melphalan Hydrochloride | 24 | 18.2 | 18.2 |
| Lopinavir And Ritonavir | 13 | 18.0 | 18.0 |
| Levetiracetam In Sodium Chloride | 68 | 17.3 | 17.3 |
| Levetiracetam Oral | 68 | 17.3 | 17.3 |
| Levetiracetam Injection | 68 | 17.3 | 17.3 |
| Melphalan | 20 | 16.6 | 16.6 |
| Bosutinib | 7 | 14.6 | 14.6 |
| Cytarabine | 45 | 14.5 | 14.5 |
| Azacitidine | 22 | 14.0 | 14.0 |
| Cyclophosphamide Injection, Solution | 118 | 13.7 | 13.7 |
| Cyclophosphamide | 118 | 13.7 | 13.7 |
| Cyclophosphamide For Injection | 118 | 13.7 | 13.7 |
| Bleomycin Sulfate | 7 | 12.7 | 12.7 |
| Imatinib Mesylate | 17 | 11.5 | 11.5 |
| Levetiracetam | 74 | 11.0 | 11.0 |
| Dasatinib | 21 | 10.7 | 10.7 |
| Doxorubicin | 48 | 10.4 | 10.4 |
| Azacitidine For | 10 | 10.3 | 10.3 |
| Nilotinib | 16 | 10.2 | 10.2 |
| Ifosfamide | 11 | 9.6 | 9.6 |
| Emtricitabine And Tenofovir Disoproxil Fumarate | 17 | 7.0 | 7.0 |
| Eltrombopag Olamine | 8 | 6.5 | 6.5 |
| Romiplostim | 5 | 6.2 | 6.2 |